Cocaine-induced granulomatosis with polyangiitis-an under-recognized condition

Charn Gill; Joseph Sturman; Leyla Ozbek; Scott R Henderson; Aine Burns; Sally Hamour; Ruth J Pepper; Lisha McClelland; Dimitrios Chanouzas; Simon Gane; Alan D Salama; Lorraine Harper

doi:10.1093/rap/rkad027

Cocaine-induced granulomatosis with polyangiitis-an under-recognized condition

Rheumatol Adv Pract. 2023 Apr 4;7(1):rkad027. doi: 10.1093/rap/rkad027. eCollection 2023.

Authors

Charn Gill¹, Joseph Sturman², Leyla Ozbek³, Scott R Henderson⁴, Aine Burns², Sally Hamour², Ruth J Pepper⁴, Lisha McClelland¹, Dimitrios Chanouzas^{1

5}, Simon Gane³, Alan D Salama⁴, Lorraine Harper^{1

5}

Affiliations

¹ Department of ENT Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
² Renal Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
³ Department of ENT surgery, Royal National ENT Hospital, University College London Hospital, London, UK.
⁴ UCL Department of Renal Medicine, , Royal Free Hospital, London, UK.
⁵ Institute Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

Abstract

Objectives: Cocaine and cocaine mixed with levamisole are increasingly used in the UK and result in significant direct nasal damage in addition to promoting vasculitis. Our aims were as follows: (1) to identify the main symptoms and presentation of cocaine-induced vasculitis; (2) to provide evidence regarding the best practice for the investigation and diagnosis of cocaine-induced vasculitis; and (3) to analyse the clinical outcomes of patients in order to understand the optimal management for the condition.

Methods: We performed a retrospective case series analysis of patients presenting with cocaine-induced midline destructive lesions or vasculitis compatible with granulomatosis with polyangiitis (GPA) from two large tertiary vasculitis clinics between 2016 and 2021.

Results: Forty-two patients (29 Birmingham, 13 London) with cocaine-induced midline lesions or systemic disease were identified. The median age was 41 years (range 23-66 years). Current cocaine use was common, and 20 of 23 samples provided were positive when routine urine toxicology was performed; 9 patients who denied ever using cocaine were identified as using cocaine based on urine toxicology analysis, and 11 who stated they were ex-users still tested positive. There was a high incidence of septal perforation (75%) and oronasal fistula (15%). Systemic manifestations were less common (27%), and only one patient had acute kidney injury. Fifty-six per cent of our patients were PR3-ANCA positive, with none testing positive for MPO-ANCA. Symptom remission required cocaine discontinuation even when immunosuppression was administered.

Conclusion: Patients with destructive nasal lesions, especially young patients, should have urine toxicology performed for cocaine before diagnosing GPA and considering immunosuppressive therapy. The ANCA pattern is not specific for cocaine-induced midline destructive lesions. Treatment should be focused on cocaine cessation and conservative management in the first instance in the absence of organ-threatening disease.

Keywords: ANCA; cocaine; drug-induced vasculitis; granulomatosis with polyangiitis; treatment.